Author

Carolina Massa

OpenAlex ID: A5075401540

Open-label, controlled, phase 2 clinical trial assessing the safety, efficacy, and pharmacokinetics of INM004 in pediatric patients with Shiga toxin-producing Escherichia coli–associated hemolytic uremic syndrome

2024 · Alicia Fayad, Iliana Principi, et al. · Pediatric Nephrology · 12

INM004: Polyclonal Neutralizing Antibodies Against Shiga Toxin as a Treatment for Hemolytic Uremic Syndrome

2025 · Marta Rivas, Mariana Pichel, et al. · Toxins · 3

Safety and effectiveness of RBD-specific polyclonal equine F(ab´)2 fragments for the treatment of hospitalized patients with severe Covid-19 disease: A retrospective cohort study

2022 · Diego H. Farizano Salazar, Fernando Achinelli, et al. · PLoS ONE · 3

Serology as an early diagnostic tool in pediatric patients with Shiga toxin-producing Escherichia coli -associated hemolytic uremic syndrome: a post hoc analysis of a phase 2 clinical trial

2026 · Stella M. Landivar, Luciano J. Melli, et al. · Journal of Clinical Microbiology · 2

Antibody Response and its Relevance for Early Diagnosis in Patients with Shiga Toxin-Producing Escherichia Coli-Associated Hemolytic Uremic Syndrome: A Post-Hoc Serological Analysis of a Phase 2 Clinical Trial

2025 · Stella Maris Landivar, Luciano J. Melli, et al. · SSRN Electronic Journal

Safety and effectiveness of RBD-specific polyclonal equine F(ab′)2 fragments for the treatment of hospitalized patients with severe Covid-19 disease: a retrospective cohort study

2022 · Diego H. Farizano Salazar, Fernando Achinelli, et al. · medRxiv

Works count: 7

Citation count: 20

H-index: 3

I10-index: 1